AVAH

Aveanna Healthcare Holdings Inc. (AVAH) is drawing attention from options traders due to high implied volatility in its December 2026 $2.50 put options, suggesting market expectations for significant price movement. Despite the volatility, the company maintains a Zacks Rank #2 (Buy) rating with recent analyst upgrades to earnings estimates, indicating a potentially developing trade opportunity.

Aveanna Healthcare (AVAH) is highlighted as a compelling value stock opportunity, holding a Zacks Rank #2 (Buy) rating and an 'A' grade for Value. The stock trades at a Forward P/E of 17.55, below its industry average of 18.43, and demonstrates attractive valuation metrics across P/S and P/CF ratios, suggesting it may be undervalued relative to its earnings outlook.

Aveanna Healthcare (AVAH), a home health care services provider, is highlighted as a stock likely to beat earnings estimates in its upcoming report. The company has a track record of beating earnings in the last two quarters with an average surprise of 33.94%. With a positive Earnings ESP of +3.28% and a Zacks Rank #2 (Buy), analysts suggest the stock has a strong probability of delivering another earnings beat.

Aveanna Healthcare (AVAH) has significantly outperformed the Medical sector year-to-date, returning 56.4% compared to the sector's 2.8% average return. The company holds a Zacks Rank #2 (Buy) with consensus earnings estimates up 23.2% in the past quarter, indicating improved analyst sentiment. Charles River Laboratories (CRL) is another Medical stock outperforming with a 48.4% year-to-date return.

Molina Healthcare is projected to report a 60.9% earnings decline in Q3 2026 with revenues falling 4.8%. The company faces multiple headwinds including a 12.7% membership decline (63% drop in Marketplace enrollment), rising medical care ratio to 93%, and falling premium revenues and investment income. The stock has a negative Earnings ESP of -3.30% and Zacks Rank #4 (Sell), making an earnings beat unlikely.

Elevance Health is projected to report Q3 2026 earnings on October 21, 2026, with consensus estimates showing a 22.7% year-over-year EPS decline to $4.66 per share and a 3% revenue decrease. The company faces challenges from declining premiums (-4.9%), reduced Commercial Individual and Medicaid membership, and a significant 23.9% plunge in Health Benefits operating income. Despite these headwinds, total expenses are expected to decline 5.5%, providing some offset.

The Ensign Group expanded its skilled nursing operations by acquiring 20 facilities across Florida, Washington, and Colorado, entering Florida for the first time. With $262.3M in cash, minimal long-term debt of $135.6M, and $591.6M in available credit, the company is well-positioned for continued growth. The acquisitions bring Ensign's total portfolio to 418 healthcare operations across 18 states.